Gastrointestinal cancer precursor risk and mortality in pancreatic intraductal papillary mucinous neoplasms: a nationwide cohort study

References

• Tanaka M, Kobayashi K, Mizumoto K, et al. Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2005;40(7):669–675. doi:10.1007/s00535-005-1646-4.
   PubMed Web of Science ®Google Scholar
• European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804. doi:10.1136/gutjnl-2018-316027.
   PubMed Web of Science ®Google Scholar
• van Huijgevoort NCM, Del Chiaro M, Wolfgang CL, et al. Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines. Nat Rev Gastroenterol Hepatol. 2019;16(11):676–689. doi:10.1038/s41575-019-0195-x.
   PubMed Web of Science ®Google Scholar
• Pugliese L, Keskin M, Maisonneuve P, et al. Increased incidence of extrapancreatic neoplasms in patients with IPMN: fact or fiction? A critical systematic review. Pancreatology. 2015;15(3):209–216. doi:10.1016/j.pan.2015.03.007.
   PubMed Web of Science ®Google Scholar
• Benarroch-Gampel J, Riall TS. Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg. 2010;2(10):363–367. doi:10.4240/wjgs.v2.i10.363.
   PubMedGoogle Scholar
• Kawakubo K, Tada M, Isayama H, et al. Incidence of extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60(9):1249–1253. doi:10.1136/gut.2010.227306.
   PubMed Web of Science ®Google Scholar
• Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch. 1994;425(4):357–367. doi:10.1007/bf00189573.
   PubMed Web of Science ®Google Scholar
• Vanella G, Crippa S, Archibugi L, et al. Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation. Br J Surg. 2018;105(4):328–338. doi:10.1002/bjs.10768.
   PubMed Web of Science ®Google Scholar
• Amini N, Habib JR, Blair A, et al. Invasive and noninvasive progression after resection of noninvasive intraductal papillary mucinous neoplasms. Ann Surg. 2022;276(2):370–377. doi:10.1097/sla.0000000000004488.
   PubMed Web of Science ®Google Scholar
• Fuji T, Umeda Y, Takagi K, et al. Optimal surveillance of intraductal papillary mucinous neoplasms of the pancreas focusing on remnant pancreas recurrence after surgical resection. BMC Cancer. 2022;22(1):588. doi:10.1186/s12885-022-09650-w.
   PubMed Web of Science ®Google Scholar
• Hirono S, Kawai M, Okada K-I, et al. Long-term surveillance is necessary after operative resection for intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2016;160(2):306–317. doi:10.1016/j.surg.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Lashkariani M. Cohort profile: ESPRESSO (epidemiology strengthened by histoPathology reports in Sweden). Clin Epidemiol. 2019;11:101–114. doi:10.2147/clep.S191914.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–667. doi:10.1007/s10654-009-9350-y.
   PubMed Web of Science ®Google Scholar
• Klöppel G. Clinicopathologic view of intraductal papillary-mucinous tumor of the pancreas. Hepatogastroenterology. 1998;45(24):1981–1985.
   PubMedGoogle Scholar
• Lv M, Zhang X, Shen Y, et al. Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors. Medicine (Baltimore). 2017;96(17):e6799. doi:10.1097/md.0000000000006799.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Appelros P, Askling J, et al. Adaptation of the Charlson Comorbidity Index for register-based research in Sweden. Clin Epidemiol. 2021;13:21–41. doi:10.2147/clep.S282475.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Svedberg P, Olén O, et al. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34(4):423–437. doi:10.1007/s10654-019-00511-8.
   PubMed Web of Science ®Google Scholar
• Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011;11(1):36. doi:10.1186/1471-2466-11-36.
   PubMedGoogle Scholar
• Bergman D, Hagström H, Capusan AJ, et al. Incidence of ICD-Based diagnoses of alcohol-related disorders and diseases from Swedish nationwide registers and suggestions for coding. Clin Epidemiol. 2020;12:1433–1442. doi:10.2147/clep.S285936.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Håberg SE, Knudsen GP, et al. Ethical aspects of registry-based research in the Nordic countries. Clin Epidemiol. 2015;7:491–508. doi:10.2147/clep.S90589.
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Atomi Y. Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol. 1999;94(2):470–473. doi:10.1111/j.1572-0241.1999.879_h.x.
   PubMed Web of Science ®Google Scholar
• Reid-Lombardo KM, Mathis KL, Wood CM, et al. Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg. 2010;251(1):64–69. doi:10.1097/SLA.0b013e3181b5ad1e.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17(5):738–753. doi:10.1016/j.pan.2017.07.007.
   PubMed Web of Science ®Google Scholar
• Koh YX, Zheng HL, Chok A-Y, et al. Systematic review and meta-analysis of the spectrum and outcomes of different histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms. Surgery. 2015;157(3):496–509. doi:10.1016/j.surg.2014.08.098.
   PubMed Web of Science ®Google Scholar
• Kim HS, Han Y, Kang JS, et al. Fate of patients with intraductal papillary mucinous neoplasms of pancreas after resection according to the pathology and margin status: continuously increasing risk of recurrence even after curative resection suggesting necessity of lifetime surveillance. Ann Surg. 2022;276(4):e231–e238. doi:10.1097/sla.0000000000004478.
   PubMed Web of Science ®Google Scholar
• Dhar VK, Merchant NB, Patel SH, et al. Does surgical margin impact recurrence in noninvasive intraductal papillary mucinous neoplasms?: a multi-institutional study. Ann Surg. 2018;268(3):469–478. doi:10.1097/sla.0000000000002923.
   PubMed Web of Science ®Google Scholar
• Luchini C, Pea A, Yu J, et al. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Mod Pathol. 2019;32(5):659–665. doi:10.1038/s41379-018-0183-7.
   PubMed Web of Science ®Google Scholar
• Gotoh Y, Ohtsuka T, Nakamura S, et al. Genetic assessment of recurrent pancreatic high-risk lesions in the remnant pancreas: metachronous multifocal lesion or local recurrence? Surgery. 2019;165(4):767–774. doi:10.1016/j.surg.2018.10.025.
   PubMed Web of Science ®Google Scholar
• Marchegiani G, Mino-Kenudson M, Ferrone CR, et al. Oncocytic-Type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis. J Am Coll Surg. 2015;220(5):839–844. doi:10.1016/j.jamcollsurg.2015.01.051.
   PubMed Web of Science ®Google Scholar